Scientific Program - PDMD

Print
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
 
 
Section Heads: Stuart Isaacson, USA, Dariusz Koziorowski, Poland & Jaime Kulisevsky, Spain
Thursday March 22, 2018
Auditorium POLIN Museum 
13:45-16:15
SESSION 3 | PLENARY LECTURES - GENETICS
  Chairs: Grzegorz Opala, Poland
13:45-14:15 The roads to decode the genetic architecture of neurodegenerative diseases: Ornit Chiba-Falek, USA
14:15-14:45 Are tau strains significant in human disease? John Trojanowski, USA
14:45-15:15 Clinical genetics of tauopathies, Zbigniew Wszolek, USA
15:15-15:45 Insights from genomic analysis of neurodegeneration: John Hardy, UK
15:45-16:15 Gene therapy in neurological diseases, Krystof Bankiewicz, USA
   
Saturday March 24, 2018
Hall A 
07:00-08:00
E-Poster Presentations
   
08:00-09:50
SESSION 22 | PARKINSON'S DISEASE (PD): ROLE OF GENETICS
  Chairs: Jesse Cedarbaum, USA & Michael Ugryumov, Russia 
08:00-08:55 The etiology of PD is predominantly genetic.
 Capsule: In recent years, many genetic risk factors have been identified mainly using GWAS, and more are to be expected, but each with a minor role. But since other risk factors are few, should we conclude that sporadic PD is primarily genetic?
08:00-08:10 Host: Andrzej Friedman, Poland
08:10-08:25
Pro: Zbigniew Wszolek, USA
08:25-08:40 Con: David Goldstein, USA
08:40-08:55 Discussion and Rebuttals
   
08:55-09:50
PD associated with lysosome dysfunction and PD associated with mitochondrial dysfunction are different diseases.
 Capsule: Several of the mutations identified in PD families are associated with lysosomal dysfunctions while others are related to mitochondrial changes. Does this mean that PD is not a single disease?
08:55-09:05 Host: Nestor Galvez-Jimenez, USA
09:05-09:20 Yes: John Hardy, UK
09:20-09:35 No: Bogdan Popescu, Romania
09:35-09:50
Discussion and Rebuttals
   
09:50-10:10 Coffee Break
 
10:10-12:10 SESSION 23 | PD: UNDERLYING MECHANISMS
  Chairs: Viktoriia Gryb, Ukraine 
10:10-11:10 Neuroimaging diagnostic workup in parkinsonian syndromes: always DAT SPECT first?
 Capsule Imaging dopamine transporter (DAT) availability in the striatum using SPECT is an established method to differentiate neurodegenerative from non-neurodegenerative parkinsonisms. However, other imaging methods such as FDG PET also show value in differentiating parkinsonisms. Which imaging method should be used first and in which cases?

This session is jointly organised by the European Association of Nuclear Medicine (EANM) and CONy.
10:10-10:20
Host: Javier Arbizu, Spain 
10:20-10:35 Pro: Elsmarieke Van De Giessen, The Netherlands 
10:35-10:50 Con: Silvia Morbelli, Italy 
10:50-11:10 Discussion and Rebuttals
   
11:10-12:10
REM sleep behavior disorder (RBD) should be considered as a precursor and marker for alpha synucleinopathies and promote therapeutic intervention.
 Capsule: RBD is not an uncommon manifestation in otherwise normal adults, and its underlying pathology is not completely known. Several reports exist of history of RBD. Is this association strong enough and does it have therapeutic implications?
11:10-11:20
Host: Irena Rektorova, Czech Republic
11:20-11:35 Pro: Tanya Gurevich, Israel
11:35-11:50 Con: Laszlo Vescei, Hungary
11:50-12:10 Discussion and Rebuttals
   
12:10-13:10
Industry Sponsored Symposium (Not for CME)
   
13:10-13:55
Lunch Break
   
13:55-15:55
SESSION 24 | PD: PATHOGENESIS AND MODELS
  Chairs: Erdem Tamguney, Germany & Urszula Fiszer, Poland
13:55-14:55 Is PD a prion disease?
13:55-14:05
Host: Daniel Kremens, USA
14:05-14:20 Pro: Erwan Bezard, France
14:20-14:35 Con: TBD
14:35-14:55
Discussion and Rebuttals
 
14:55-15:55 Animal models are useful in understanding PD pathogenesis.
 Capsule: Several animal models of PD have been developed over the years, and these are commonly used in searching for drugs. Can they tell us something about the pathogenesis of the disease?
14:55-15:05
Host: Laszlo Vescei, Hungary
15:05-15:20 Pro: Bogdan Popescu, Romania
15:20-15:35 Con: David Goldstein, USA
15:35-15:55 Discussion and Rebuttals
 
15:55-16:15 Coffee Break
 
16:15-19:00
SESSION 25 | PD: STAGING, PROTECTION, AND TREATMENT
  Chairs: Wael Ibrahim, Egypt & Matej Skorvanek, Slovak Republic
16:15-17:10 Is Braak staging true for all PD?
16:15-16:25
Host: Kurt Jellinger, Austria
16:25-16:40
Yes: Albert Ludolph, Germany
16:40-16:55 No: Marios Politis, UK
16:55-17:10
Discussion and Rebuttals
   
17:10-18:05
Is vagotomy protective against PD?
 Capsule: Some data suggests that the first changes in PD occur in the gastrointestinal tract, including the stomach, and are then transmitted to the brain through the vagus nerves. Will vagotomy prevent PD and should it be proposed to those who are at high risk?
17:10-17:20 Host: Mark Lew, USA
17:20-17:35 Yes: Irena Rektorova, Czech Republic
17:35-17:50 No: Abdelhamid Benazzouz, France
17:50-18:05 Discussion and Rebuttals
   
18:05-19:00  Is Tai-Chi effective in the management of PD?
 Capsule: Traditional Chinese Quigong excercises include Tai Chi which is considered safe and has been suggested to anneliorate PD symptoms. Should this approach be promoted?  
18:05-18:15 Host: Dafin Muresanu, Romania
18:15-18:30 Yes: Agata Milert, Poland
18:30-18:45 No: Jozef Opara, Poland
18:45-19:00 Discussion and Rebuttals
 
Hall D 
16:15-17:10
SESSION 39 | PARKINSON'S DISEASE (PD) – COMPLICATIONS AND TREATMENT (Not for CME)
  Chairs: TBA
16:15-17:05 Should dyskinesia be treated with non-dopaminergic strategies?
16:15-16:25
Host: Rajesh Pahwa, USA
16:25-16:40
Yes: Stuart Isaacson, USA
16:40-16:55 No: Daniel Kremens, USA
16:55-17:10
Discussion and Rebuttals
   
17:10-18:05
Should PD Psychosis be treated early with antipsychotics?
17:10-17:20 Host: Mark Lew, USA
17:20-17:35 Yes: Daniel Kremens, USA
17:35-17:50 No: Tanya Simuni, USA
17:50-18:05 Discussion and Rebuttals
   
18:05-19:00  Neurogenic orthostatic hypotension is under recognized and undertreated in PD.
18:05-18:15 Host: Fiona Gupta, USA
18:15-18:30 Yes: Rajesh Pahwa, USA
18:30-18:45 No: Mark Lew, USA
18:45-19:00 Discussion and Rebuttals
 
SUNDAY March 25, 2018
Hall A 
08:00-10:40
SESSION 40| MOVEMENT DISORDERS
  Chairs: Cristian Falup-Pecurariu, Romania & Amos Korczyn, Israel
08:30-09:35 Is Parkinson's disease (PD) more common in patients with essential tremor?
08:30-08:40 Host: Rajesh Pahwa, USA
08:40-09:00
Pro: Jaroslaw Slawek, Poland
09:00-09:20 Con: Dariusz Koziorowski, Poland
09:20-09:35 Discussion and Rebuttals
   
09:35-10:40
With the use of atypical neuroleptics, tardive syndromes have practically disappeared.
09:35-09:45 Host: Pedro J Garcia Ruiz, Spain
09:45-10:05 Yes: Jaime Kulisevsky, Spain
10:05-10:25 No: Stuart Isaacson, USA
10:25-10:40
Discussion and Rebuttals
   
10:40-11:00 Coffee Break
 
11:00-13:00
SESSION 41 | PARKINSON'S DISEASE (PD) – THERAPY (Not for CME)
  Chairs: TBA
11:00-12:00 Non-oral therapies should be used before DBS in treating advanced motor fluctuations
11:00-11:10 Host: Stuart Isaacson, USA
11:10-11:25
Yes: European per Brittania
11:25-11:40 No: Fiona Gupta, USA
11:40-12:00 Discussion and Rebuttals
   
12:00-13:00
Should Nonmotor Symptoms be prioritized over Motor Symptoms at clinic visits?
12:00-12:10 Host: Daniel Kremens, USA
12:10-12:25 Yes: Mark Lew, USA
12:25-12:40 No: Rajesh Pahwa, USA
12:40-13:00
Discussion and Rebuttals